Brainstorm Cell (BCLI) director discloses 150,000-share stock option grant

Rhea-AI Filing Summary

Brainstorm Cell Therapeutics director Peter Joe Pitts reported initial holdings of a stock option to buy common shares. The option covers 150,000 underlying shares of common stock at an exercise price of $0.68 per share and expires on May 25, 2036.

According to the disclosures, the option was granted under the company’s 2014 Stock Incentive Plan. It vests 50% on the grant date and 50% on the six-month anniversary of the grant, if Pitts continues serving the company through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pitts Peter Joe

Role null

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 150,000 shares (Direct, null)

Footnotes (1)

1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The Stock Option shall vest as to (i) 50% of the award on the date of grant, and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains in service with the Issuer through each applicable vesting date. Based on the closing price per share of the Issuer's common stock on May 22, 2026, the last business day prior to the grant date.

Key Figures

Underlying shares: 150,000 shares Exercise price: $0.68 per share Option expiration: May 25, 2036

3 metrics

Underlying shares 150,000 shares Common stock underlying reported stock option holding

Exercise price $0.68 per share Stock option (Right to Buy) exercise price

Option expiration May 25, 2036 Expiration date of reported stock option

Key Terms

Stock Option (Right to Buy), 2014 Stock Incentive Plan, vesting

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy) with underlying common stock"

2014 Stock Incentive Plan financial

"options granted under the Issuer's 2014 Stock Incentive Plan"

vesting financial

"50% vests on the grant date and 50% on the six-month anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pitts Peter Joe

(Last) (First) (Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/25/2026

3. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	(2)	05/25/2036	Common Stock	150,000	$0.68(3)	D

Explanation of Responses:

1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.

2. The Stock Option shall vest as to (i) 50% of the award on the date of grant, and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains in service with the Issuer through each applicable vesting date.

3. Based on the closing price per share of the Issuer's common stock on May 22, 2026, the last business day prior to the grant date.

Remarks:

Exhibit List - Exhibit 24.1 - Power of Attorney

	/s/ Peter J. Pitts	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did BCLI director Peter Joe Pitts report in this Form 3?

Peter Joe Pitts reported holding a stock option to buy 150,000 shares of Brainstorm Cell Therapeutics common stock. The option was granted under the company’s 2014 Stock Incentive Plan and represents his initial reported derivative ownership as a director.

What are the key terms of Peter Joe Pitts’ BCLI stock option?

The reported stock option allows purchase of 150,000 Brainstorm Cell Therapeutics common shares at an exercise price of $0.68 per share. It expires on May 25, 2036, giving the director a long-dated right to acquire company stock at that price.

How does the BCLI stock option for Peter Joe Pitts vest?

The option vests in two equal parts. Half of the award vests on the grant date, and the remaining half vests on the six-month anniversary, provided Peter Joe Pitts remains in service with Brainstorm Cell Therapeutics through each vesting date.

Under which plan was Peter Joe Pitts’ BCLI option granted?

The option was granted under Brainstorm Cell Therapeutics’ 2014 Stock Incentive Plan. This plan governs equity-based awards, including stock options, granted to eligible participants such as directors, aligning their interests with long-term shareholder value.

How was the exercise price for Peter Joe Pitts’ BCLI option determined?

The $0.68 per share exercise price was based on the closing price of Brainstorm Cell Therapeutics’ common stock on May 22, 2026, the last business day before the grant date. This pegs the option strike to the then-prevailing market price.